Vibegron : for treating symptoms of overactive bladder syndrome

NICE has issued guidance on the use of Vibegron (marketed as Obgemsa by Pierre Fabre) for the treatment of overactive bladder (OAB) syndrome. OAB is characterized by symptoms such as urgency, increased frequency of urination, and incontinence, significantly impacting quality of life.

Vibegron has been granted marketing authorization for the symptomatic treatment of adult patients with OAB. The recommended dosage, as outlined in the summary of product characteristics, allows healthcare professionals to appropriately administer the drug. As of July 2024, the list price of vibegron is £26.68 per pack of 30 tablets (excluding VAT), making it a competitive option in the pharmacological management of OAB symptoms.

Recommendation	Explanation
1.1	Vibegron is recommended for treating symptoms of overactive bladder syndrome in adults if antimuscarinic medicines are unsuitable, ineffective, or cause unacceptable side effects.
1.2	If vibegron is considered one of several suitable treatments, the least expensive option should be used, considering administration costs, dosages, price per dose, and commercial arrangements.
1.3	The recommendation does not affect patients who started vibegron treatment before this guidance was issued. Those already on treatment may continue as per previous funding arrangements until a change is agreed between the patient and healthcare professional.

Why These Recommendations...

Try our Free Plan to get the full article.